Substance / Medication

Efanesoctocog alfa

Overview

Active Ingredient
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
RxNorm CUI
2631084

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efanesoctocog Alfa Versus Emicizumab in Adolescent and Adult Patients With Haemophilia A Without Inhibitors.
Álvarez Román María Teresa, Kragh Nana, Guyot Patricia et al. · Adv Ther · 2025
PMID: 39576432Meta-AnalysisFull text (PMC)
Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in People Living With Severe Hemophilia A : A Cost-Effectiveness Analysis.
Ito Satoko, Potnis Kunal C, Harvey Jessica Preston et al. · Ann Intern Med · 2025
PMID: 40258278ObservationalFull text (PMC)
Accurate evaluation of factor VIII activity of efanesoctocog alfa in the presence of emicizumab.
Nougier Christophe, Pipe Steven W, Pabinger Ingrid et al. · J Thromb Haemost · 2025
PMID: 39798924Observational
Practical challenges associated with efanesoctocog alfa (ALTUVIIIO) prophylaxis in a 19-month-old male with severe hemophilia A.
Mistretta Jessica N, Español Maria G, Tarantino Michael D et al. · Pediatr Blood Cancer · 2024
PMID: 38753403Case Report
Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa.
Ryu Justine H, Bauer Kenneth A, Schulman Sol · J Thromb Haemost · 2023
PMID: 37734716Case Report
Efanesoctocog Alfa Prophylaxis in a Patient With Combined Mild Hemophilia A and Type 1 von Willebrand Disease.
Uwaezuoke Destiny, Pham An, Garcia Jessica · Pediatr Blood Cancer · 2026
PMID: 41121639Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Efanesoctocog alfa (substance)
SNOMED CT
1363054004
UMLS CUI
C5421030
RxNorm CUI
2631084

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.